Zoetis (NYSE:ZTS) Given New $85.00 Price Target at Barclays

Zoetis (NYSE:ZTS) had its target price decreased by investment analysts at Barclays from $136.00 to $85.00 in a research note issued on Wednesday,Benzinga reports. The brokerage currently has an “equal weight” rating on the stock. Barclays‘s target price would indicate a potential upside of 18.25% from the stock’s current price.

A number of other equities analysts also recently commented on ZTS. Weiss Ratings downgraded Zoetis from a “sell (d+)” rating to a “sell (d)” rating in a research note on Friday, June 12th. Argus reiterated a “hold” rating on shares of Zoetis in a research report on Wednesday, May 27th. Leerink Partners reissued a “market perform” rating on shares of Zoetis in a report on Tuesday, March 10th. Morgan Stanley restated an “overweight” rating and set a $115.00 price objective on shares of Zoetis in a research report on Friday, May 15th. Finally, UBS Group dropped their target price on Zoetis from $130.00 to $99.00 and set a “neutral” rating on the stock in a research report on Friday, May 8th. Seven analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $126.92.

Zoetis Stock Down 1.9%

ZTS stock opened at $71.88 on Wednesday. The firm has a market cap of $30.13 billion, a price-to-earnings ratio of 11.92, a PEG ratio of 1.14 and a beta of 0.75. Zoetis has a 1-year low of $71.47 and a 1-year high of $161.77. The firm has a fifty day moving average price of $86.77 and a two-hundred day moving average price of $110.27. The company has a debt-to-equity ratio of 2.80, a current ratio of 3.15 and a quick ratio of 1.91.

Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Thursday, May 7th. The company reported $1.53 EPS for the quarter, missing the consensus estimate of $1.60 by ($0.07). Zoetis had a net margin of 27.80% and a return on equity of 66.85%. The business had revenue of $2.26 billion during the quarter, compared to analyst estimates of $2.30 billion. During the same period last year, the firm posted $1.48 earnings per share. The company’s quarterly revenue was up 2.9% on a year-over-year basis. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. Research analysts predict that Zoetis will post 6.87 EPS for the current year.

Insider Buying and Selling at Zoetis

In other Zoetis news, Director Michael B. Mccallister purchased 3,000 shares of Zoetis stock in a transaction on Monday, May 11th. The stock was bought at an average price of $77.76 per share, for a total transaction of $233,280.00. Following the transaction, the director owned 24,524 shares of the company’s stock, valued at $1,906,986.24. The trade was a 13.94% increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Frank A. Damelio purchased 6,650 shares of the stock in a transaction dated Wednesday, May 13th. The shares were acquired at an average cost of $75.39 per share, for a total transaction of $501,343.50. Following the completion of the acquisition, the director directly owned 21,458 shares of the company’s stock, valued at approximately $1,617,718.62. This trade represents a 44.91% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have acquired 11,650 shares of company stock valued at $886,384 in the last quarter. Corporate insiders own 0.22% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Global Wealth Strategies & Associates bought a new stake in Zoetis during the fourth quarter worth approximately $25,000. Prosperity Bancshares Inc bought a new position in Zoetis during the 4th quarter valued at $25,000. Cassaday & Co Wealth Management LLC bought a new position in Zoetis during the 1st quarter valued at $28,000. Lodestone Wealth Management LLC acquired a new position in shares of Zoetis during the 4th quarter valued at $30,000. Finally, Root Financial Partners LLC increased its position in shares of Zoetis by 66.5% during the 1st quarter. Root Financial Partners LLC now owns 258 shares of the company’s stock valued at $30,000 after purchasing an additional 103 shares during the period. 92.80% of the stock is currently owned by institutional investors.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.